Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars - PubMed

Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars

Z Qu et al. Infect Immun. 1993 Apr.

Abstract

A monoclonal antibody (MAb), C10, that neutralized in vitro the infectivity of serovars C, I, J, and L3 (members of the C and C-related complexes) of Chlamydia trachomatis was identified. Of the 15 major serovars and the mouse pneumonitis strain of C. trachomatis, Chlamydia psittaci, and Chlamydia pneumoniae, which were used as nontreated and heat-treated (56 degrees C, 30 min) antigens in a dot blot assay, only serovars C, I, J, and L3 were recognized with both the native and treated antigens. Western blot (immunoblot) results showed that MAb C10 recognized the major outer membrane protein of these four serovars. Overlapping hexameric peptides corresponding to variable domains (VDs) I, II, III, and IV of the major outer membrane protein of C. trachomatis serovar C were synthesized, and peptide screening showed that MAb C10 mapped to the VD I amino acid sequence VAGLQNDPT. Results of an in vitro neutralization assay correlated with those of the indirect immunofluorescence assay, Western blot, and dot blot assay in that only serovars C, I, J, and L3 were neutralized by MAb C10. In vitro competitive neutralization experiments, using a peptide representing VD I of serovar C to compete with C. trachomatis serovar C for MAb C10 binding, revealed that both serological and neutralizing activities of MAb C10 were inhibited by the VD I peptide. In an in vivo toxicity/infectivity assay using serovar L3 pretreated with MAb C10, there was 100% survival of mice infected with a lethal dose at 48 h. In contrast, the control group, consisting of mice injected with the same dose of L3 pretreated with a MAb that does not recognize L3, had no survivors during a 48-h observation period. In summary, since the surface-exposed contiguous epitope recognized by MAb C10 binds neutralizing antibodies that are subspecies specific for the C and C-related complexes, it should be considered for inclusion in the development of a chlamydial vaccine.

Similar articles

• Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies.

  Peterson EM, Cheng X, Markoff BA, Fielder TJ, de la Maza LM. Peterson EM, et al. Infect Immun. 1991 Nov;59(11):4147-53. doi: 10.1128/iai.59.11.4147-4153.1991. Infect Immun. 1991. PMID: 1718870 Free PMC article.

• Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis.

  Zhang YX, Stewart S, Joseph T, Taylor HR, Caldwell HD. Zhang YX, et al. J Immunol. 1987 Jan 15;138(2):575-81. J Immunol. 1987. PMID: 3540122

• Immunologic characterization of a cloned fragment containing the species-specific epitope from the major outer membrane protein of Chlamydia trachomatis.

  Toye B, Zhong GM, Peeling R, Brunham RC. Toye B, et al. Infect Immun. 1990 Dec;58(12):3909-13. doi: 10.1128/iai.58.12.3909-3913.1990. Infect Immun. 1990. PMID: 1701415 Free PMC article.

• Identification and characterization of T helper cell epitopes of the major outer membrane protein of Chlamydia trachomatis.

  Su H, Morrison RP, Watkins NG, Caldwell HD. Su H, et al. J Exp Med. 1990 Jul 1;172(1):203-12. doi: 10.1084/jem.172.1.203. J Exp Med. 1990. PMID: 1694217 Free PMC article.

Cited by

• Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.

  Frietze KM, Lijek R, Chackerian B. Frietze KM, et al. Expert Rev Vaccines. 2018 Nov;17(11):959-966. doi: 10.1080/14760584.2018.1534587. Epub 2018 Oct 20. Expert Rev Vaccines. 2018. PMID: 30300019 Free PMC article.

• Species-, serogroup-, and serovar-specific epitopes are juxtaposed in variable sequence region 4 of the major outer membrane proteins of some Chlamydia trachomatis serovars.

  Batteiger BE, Lin PM, Jones RB, Van Der Pol BJ. Batteiger BE, et al. Infect Immun. 1996 Jul;64(7):2839-41. doi: 10.1128/iai.64.7.2839-2841.1996. Infect Immun. 1996. PMID: 8698520 Free PMC article.

• The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific epitope.

  Batteiger BE. Batteiger BE. Infect Immun. 1996 Feb;64(2):542-7. doi: 10.1128/iai.64.2.542-547.1996. Infect Immun. 1996. PMID: 8550205 Free PMC article.

• Characterization of the murine antibody response to peptides representing the variable domains of the major outer membrane protein of Chlamydia pneumoniae.

  Peterson EM, Cheng X, Qu Z, de La Maza LM. Peterson EM, et al. Infect Immun. 1996 Aug;64(8):3354-9. doi: 10.1128/iai.64.8.3354-3359.1996. Infect Immun. 1996. PMID: 8757875 Free PMC article.

• Vaccines for bacterial sexually transmitted infections: a realistic goal?

  Sparling PF, Elkins C, Wyrick PB, Cohen MS. Sparling PF, et al. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2456-63. doi: 10.1073/pnas.91.7.2456. Proc Natl Acad Sci U S A. 1994. PMID: 8146139 Free PMC article. Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Immune Epitope Database and Analysis Resource